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A B S T R A C T
Purpose: The long-term safety and efﬁcacy of levetiracetam (LEV) was evaluated as add-on therapy in
focal epilepsy patients (n = 491) aged at least 65 years who failed at least one monotherapy.
Methods: Patients (n = 491) with focal epilepsy treated with at least one antiepileptic drug in
monotherapy with insufﬁcient seizure control were included in this prospective open-label study. The
recommended LEV dose range was 1000–3000 mg per day. Follow-up visits were done approximately
after 3, 6 and 12months. Safety and efﬁcacy was analysed based on all patients who received LEV (safety
population, n = 491) and all patients who were seen at all visits and completed the trial (per protocol
population, n = 364).
Results: Patients (53% men, median age 71 years) had a total of 97 adverse events (AEs) reported in 53
patients. The most common AEs were fatigue and restlessness (9.7% each of all AEs). A total of 35 serious
AEs occurred in 19 patients (3.9% of the safety population), all but one unrelated to the studymedication.
Mean monthly seizure frequency dropped signiﬁcantly from 7.0 (SD 8.7, range 1–85, median 4) at
baseline to 1.7 (SD 2.9, range 0–29, median 1) at 3month, 1.2 (SD 2.6, range 0–30, median 0) at 6, and 1.4
(SD 6.6, range 0–99, median 0) at 12 months, corresponding to a reduction of 75.7%, 82.9%, and 80.0%
relative to baseline. Seizure freedomwas reported by 42%, 57.7%, and 58% of patients during the previous
period at 3, 6 and 12 months follow-up, respectively.
Conclusions: Add-on treatment with LEV in elderly patients with focal epilepsy was safe and efﬁcient.
Levetiracetam might be considered as a suitable drug in the elderly.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Establishing effective and well tolerated anti-epileptic treat-
ment is particularly important for the elderly population. The aim
of care in this vulnerable patient population is the best quality of
life with no seizures and the fewest adverse effects from treatment
with no drug interactions. Treatment of older patients with anti-
epileptic drugs (AEDs) is complex and requires special attention to
age-related alterations of drug tolerability and metabolism.
Patients often have multiple diseases with multiple drug therapy
and management requires understanding of the age-related
changes in pharmacokinetics and pharmacodynamics of both
AEDs and other medication.1,2 Epidemiological data show that* Corresponding author. Tel.: +49 6131 17 5275; fax: +49 6131 17 475275.
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1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.12.015among all age groups the prevalence of epilepsy is highest above
the age of 65.3 In fact, after stroke and dementia, epileptic seizures
and epilepsy represent the third most common health problem in
the elderly, cerebrovascular disease being the singlemost common
aetiology underlying epilepsy in the elderly people.4,5
Results of the veteran administration study (ILAE Class I
evidence) on treatment of geriatric epilepsy suggest that
lamotrigine and gabapentin are equally effective as carbamazepine
but much better tolerated than immediate release carbamazepine
(CBZ-IR).6 Another study of epilepsy in the elderly (ILAE Class II)
found lamotrigine more effective than CBZ-IR, due to better
tolerability of the drug.7 Finally, another study using the more
appropriate slow-release carbamazepine (CBZ-SR) as comparator
suggests similar efﬁcacy and tolerability of CBZ-SR and lamo-
trigine.8 Themajor limitation of this study is that it only had an 80%
power to detect a 20% difference in effectiveness between
treatment arms only. Therefore, the trial might have been
underpowered in order to detect a possible difference between
treatment arms.vier Ltd. All rights reserved.
Table 1
Characteristics of patients exposed to medication (safety population n=491) and
those with complete follow-up data (PP population n=364).
Safety population PP population
Number (n) 491 364
Median age (min–max) 71 (65–101) 71 (65–101)
Gender- n male/female (%) 260 (53)/231 (47) 197 (54.1)/167 (45.9)
Median duration of epilepsy
(range, years)
5 (0–75) 5.0 (0–75)
Simple partial (%) 32.0 33.8
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as effective, experts advise the use of lamotrigine or levetiracetam
(LEV) as initial monotherapy for elderly adults with focal
epilepsy.9,10 Levetiracetam has a distinctive clinical proﬁle
including anticonvulsive properties against focal and generalized
epilepsies with very few toxic effects.11 The pharmacokinetic
proﬁle is very favourable with linear kinetics, low protein binding,
no relevant hepatic metabolism, and a low potential for drug
interactions. Clinical trials have conﬁrmed the safety and efﬁcacy
of LEV in patients with focal epilepsies in a dose range of 1000–
3000 mg.12–14 Therefore, LEV might be an appropriate candidate
for the use in the elderly population. There are, however, only four
studies carried out on small numbers of patients,making it difﬁcult
to determine the practical value of LEV in elderly patients with
epilepsy.15–18
Given the paucity of data on its efﬁcacy and safety in this
particular section of the population, the aim of this open label,
prospective study was to assess the impact of LEV as an add-on
therapy on seizure frequency in patients with focal epilepsy aged
65 or above, who failed at least one monotherapy. In addition, this
study was designed to document adverse events and treatment
success over a longer time period than assessed in regulatory trials
carried out mostly only over 12–16 weeks. Regulatory trials are
mainly done in younger and more severely affected individuals
with a long history of drug-resistant epilepsy. In regulatory trials
dosing is ﬁxed and patients have fewer comorbid conditions
making it difﬁcult to transfer results into clinical practice. As a
result, this study was conducted to provide evidence for clinicians,
which would allow them to form an opinion upon the practical,
real-life usefulness of LEV outside the stringent boundaries of
randomized-controlled protocols.
2. Methods
For the purposes of this study patients with focal epilepsy were
treatedprospectivelywithLEVasadd-onantiepilepticmedication in
an open, observational design over a period of one year.With ethical
approval, this work was carried out in accordance with The Code of
Ethics of the World Medical Association (Declaration of Helsinki,
http://www.wma.net/en/20activities/10ethics/10helsinki/
index.html) for experiments involving humans, all subjects gave the
written and informed consent to participate in the study. Patients
wereeligible for the study if (1) theywere65yearsofageorolder, (2)
had focal epilepsy according to the deﬁnition of the International
League against Epilepsy and (3) were treatedwith at least one other
antiepileptic drug in monotherapy with insufﬁcient seizure
control.19 The initial starting dose recommended by the protocol
was 500 mg LEV BID. This dose could be increased according to
efﬁcacy and side effects at the discretion of the investigator by steps
of 500 mg BID every 14–28 days up to a maximum daily dose of
1500 mg BID. In patients with renal insufﬁciency the maximum
daily dosewas adjusted if the creatinine clearancewas below80ml/
min to 2000mg, with further adjustments to 1500 and 1000mg
with a clearance below 50 or 30 ml/min, respectively. After
inclusion, follow-up visits were done at 3, 6 and 12 months. At
each visit the type and number of seizures, side effects and
concomitant drug use was documented. In addition, efﬁcacy and
tolerability was rated by physicians and patients on a ﬁve-point
analogue scale (grades from ‘‘very good’’ to ‘‘insufﬁcient’’) at last
follow-up. All datawere collectedusing paper case report forms. For
the purpose of data analysis of this clinical trial two different
populations were deﬁned and analysed separately:Complex partial (%) 43.0 42.9
Secondary generalized (%) 52.5 52.7 s
Generalized tonic-clonic (%) 15.1 17.3afety-population (n = 491): including all patients who received
LEV. per protocol-population (n = 364): patients who were seen at all
visits and completed the trial.
Descriptive statistics were calculated for group characteristics
like demographic data, type of epilepsy, seizure types, and
frequency of side effects. Analyses of differences of these variables
were conducted using Chi-square tests or Fisher exact tests. For
numerical, normally distributed data two-sided t-tests were used.
Changes in seizure frequencywere analysed using ANOVA and post
hoc two-sided t-tests. A p-value < 0.05 was considered as
signiﬁcant. Due to the open and observational design of the study,
inference statistics were carried out exploratively. Accordingly,
alpha-adjustments were not conducted.
3. Results
3.1. Safety population
A total of 491 patients (260 men, 228 women) with a mean age
of 72.4 years (SD 6.2, range 65–101, median 71) and a mean
duration of epilepsy of 13 years (SD 16.8, range 0–75, median 5)
participated in the trial (safety population). Patient characteristics
are summarized in Table 1. The majority of patients (70.7%,
n = 347) were between 65 and 74 years old, 125 patients (25.5%)
were between 75 and 84 years, and 19 patients (3.9%) 85 years or
older. Seizures were classiﬁed as simple partial (32%), complex-
partial (43%), secondary generalised (52.5%) or generalized tonic-
clonic without prior seizure type (15.1%). Simple partial, complex
partial, secondary generalized and generalized tonic-clonic sei-
zures occurred in 34.3%, 44.7%, 50.4% and 17.3% of patients less
than 75 years and in 28%, 39.2%, 57.6% and 9.6% of those between
75 and 84 years of age, respectively. Explorative analysis revealed
that generalized tonic-clonic seizures without prior seizure type
occurred more frequently in younger (65–74 years) than in older
patients (75–84 years) (17.3% vs. 9.6%; x2 = 4.2, p < 0.05).
Frequency of other seizure types did not differ with age. The
number of patients aged 85 years or older was too small for
statistical comparisons. The aetiology of epilepsy was cerebrovas-
cular (40.9%), trauma (9.8%), tumour (7.1%), dementia (6.5%),
metabolic (1.8%), toxic or infectious (1.6% each) and was unknown
in 30.7% of patients. Aetiologies like cerebrovascular disease or
dementia increased (cerebrovascular 38.3–44.0% (ns), dementia
4.0–13.6%; x2 = 13.7, p < 0.001) while others were less frequent
(trauma 11.5–6.4% (ns), tumour 8.9–3.2%; x2 = 4.4, p < 0.05) when
patients aged between 65 and 74 years were compared to those
aged between 75 and 84 years. Of all patients, 13.4% had previously
been treated with two different AEDs and 0.4% had three previous
antiepileptic treatments. Concomitant diseases (other than epi-
lepsy) were noted in 82.7% of patients. Two-thirds had one or two
concomitant diseases with hypertension (33%), diabetes (12.2%),
coronary artery disease (7.5%) and depression (4.5%) being the
Table 2
Concomitant AEDs (PP population).
AEDa name n %
Valproic acid 125 35.6
Carbamazepine 115 32.8
Phenytoin 34 9.7
Oxcarbazepine 20 5.7
Lamotrigine 13 3.7
Gabapentin 12 3.4
Primidone 9 2.6
Phenobarbital 6 1.7
Barbexaclone 4 1.1
Topiramate 4 1.1
Clonazepam 2 0.6
Lorazepam 2 0.6
Clobazam 1 0.3
Nitrazepam 1 0.3
Diazepam 1 0.3
Sultiame 1 0.3
Vigabatrin 1 0.3
a Antiepileptic drug.
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antiepileptic drugs (29.3% one, 21% two, 10.2% three other non-
AEDs) and the maximum number of concomitant drugs was 15 in
one patient. The most frequently noted concomitant non-antiepi-
leptic drugs were platelet aggregation inhibitors (24%), beta
blocking agents (23.2%), ACE inhibitors (18%), insulin (16.1%),
sulfonamides (10.6%), and digitalis (7.9%).
3.2. Per-protocol population
The per-protocol population (PP population, n = 364), consisted
of 197 (54%) men and 167 women (46%) with a mean age of 72.1
years (SD 5.7, range 65–101, median 71) and a mean duration of
epilepsy of 12.9 years (SD 16.5, range 0–75, median 5). Two
hundred and sixty-six patients (73.1%) were between 65 and 74
years old, 89 (24.5%) were between 75 and 84 years old, and 9
(2.5%) were 85 years or older. Seizure classiﬁcation consisted of
33.8% patients with simple and 42.9% with complex-partial
seizures, 52.7% also had secondary generalized seizures and in
17.3% of the patients generalized tonic-clonic seizures occurred
without preceding seizure type. Generalized tonic-clonic seizures
without preceding seizure type were more frequent in younger
(65–74 years) than in older (75–84 years) patients (19.5% vs.
10.1%; x2 = 4.2, p < 0.05). In the PP population the aetiology of
epilepsy was cerebrovascular (40.1%), trauma (12.1%), tumour
(6.9%), dementia (5.2%), metabolic (1.6%), toxic (1.4%), infectious
(1.9%) or unknown (30.8%). Like in the safety population,
aetiologies like cerebrovascular disease (37.6% vs. 44.9%, ns) or
dementia (3.4–11.2%, x2 = 8.1, p < 0.01) increased with age while
others were less frequent (trauma 13.9–7.9% (ns), tumour 9.0–
1.1%, x2 = 6.4, p < 0.05) when patients aged between 64 and 74
years were compared to those aged between 75 and 84 years. Most
patients had only one previous AED treatment (86.2%). Two or
more previous AED treatments were reported in 70 patients
(13.8%) of the PP population. Given the inclusion criteria all
patients were at least on one other AED when included into the
study. Themost frequent concomitant AEDswere valproic acid and
carbamazepine (Table 2).[()TD$FIG]
Fig. 1. Percentage of patients taking LEV as add-on treatment (m3.3. Levetiracetam dosage
The Levetiracetam dosage of the safety population is shown in
Fig. 1. At ﬁrst visit, patients received a mean daily starting dose of
788.2 mg LEV (SD 334.6 mg, range 250–3000 mg, median
1000 mg), mostly consisting of either 1000 mg (53%) or 500 mg
(36.5%) per day.
Only 6.7% of patients received 250 mg daily as the starting dose,
more frequently in older (75–84 years, 12%) than younger (65–74
years, 4.3%) patients (x2 = 9.1, p < 0.01). The dose of LEV was
increased over the course of the trial. Mean LEV dosages at 3, 6, and
12 months were 1573.2 mg (SD 709 mg, 250–5000 mg, median
1500 mg), 1796.3 mg (SD 732 mg, 250–4000 mg, median
2000 mg), and 2083.3 mg (SD 890 mg, 250–4000 mg, median
2000 mg). The most frequently used daily dose was 1000 mg
(69.3%) at 3, 1500 mg (70.4%) at 6, and 2000 mg (68.1%) at 12
month follow-up. The percentage of patients on the maximum
daily dose of 3000 mg increased from 2.8% at 3month follow-up tog per day) at study entry and 3, 6, and 12 months follow-up.
Table 3
Incidence of non-serious and serious adverse events in n=491 patients receiving
levetiracetam adjuctive therapy (safety-population).
Adverse event (in n=34 patients) N %
Fatigue 6 9.7
Restlessness 6 9.7
Depressive disorder 5 8.1
Gait instability 5 8.1
Vertigo 5 8.1
Aggressiveness/irritability 4 6.5
Sleep disturbance 3 4.8
Tremor 3 4.8
Allergic rash 2 3.2
Drowsiness 2 3.2
Mental slowing 2 3.2
Pruritus 2 3.2
Urinary tract infection 2 3.2
Worsening of arterial hypertension 2 3.2
Adaptive disorder 1 1.6
Cerebrovascular insufﬁciency 1 1.6
Confusion 1 1.6
Disturbance of memory 1 1.6
Headache 1 1.6
Incontinence 1 1.6
Joint pain 1 1.6
Mild sedation 1 1.6
Nausea 1 1.6
Paranoid disorder 1 1.6
Polymyopathy 1 1.6
Tachycardia 1 1.6
Weight gain 1 1.6
62
Serious adverse eventsa (in n=19 patients) N % Relation
Pneumonia 7 15.9 Unlikely
Epileptic seizures 5 11.4 Unlikely
Cardiopulmonary failure 4 9.1 Unlikely
Serial GTCS 3 6.8 Unlikely
Myocardial infarct 2 4.5 Unlikely
Stroke 2 4.5 Unlikely
Allergic rash 1 2.3 Unlikely
Confusion 1 2.3 Unlikely
Depressive disorder 1 2.3 Unlikely
Deteriorating neoplasma 1 2.3 Unlikely
Fever 1 2.3 Unlikely
Lack of efﬁcacy 1 2.3 Probable
Loss of consciousness 1 2.3 Unlikely
Meningeoma 1 2.3 Unlikely
Pericardial effusion 1 2.3 Unlikely
Pruritus 1 2.3 Unlikely
Raised intracranial pressure/oedema 1 2.3 Unlikely
Somnolence 1 2.3 Unlikely
35
a Excluding n=9 patients who died unrelated, GTCS=generalized tonic-clonic
seizures.
K.J. Werhahn et al. / Seizure 20 (2011) 305–31130810.8% at 12 month follow-up (Fig. 1). At the last follow-up visit,
older (75–84 years) patients received lower LEV dosages than
younger (65–74 years) patients (>1000 mg/day 37.0% vs. 65.5%,
x2 = 22.9, p < 0.001). Gender, duration of epilepsy or the number of
previous AED treatments did not inﬂuence the LEV dose.
In the PP population the initial mean daily dosage of LEV was
797.4 (SD 318 mg, range 250–3000mg, median 1000 mg) 54.9%
receiving 1000 mg and 36.5% receiving 500 mg per day. A change of
dose occurred most often at ﬁrst follow-up (3 months, 49.2%, mean
daily dose 1606 mg, SD 660.8 mg). At 6 and 12 months further
changes were made in 22.3% and 15.7% of patients and mean daily
dosage was 1 818.8 mg (SD 708.2 mg) and 2155.7 (SD 869.1 mg),
respectively. In 40.1% thepatient’s dosagewas increased; in 19.5% to
1 000 mg, in 9.6% to 1500mg and in 3.8% to 2000 mg. Overall,
median daily doses of the PP populationwere not different from the
safety population, i.e. 1000 mg after the ﬁrst visit, and 1500 mg,
2000 mg and 2000mg at 3, 6 and 12 months follow-up. Dose
increaseswere donemore frequently in patients aged 65 to 74 years
compared topatients agedbetween75and84years (25.8%vs. 35.3%,
X2 = 16.5, p < 0.001). In 50.8%, 46.2% and 83.5% of patients the LEV
dosage remained unchanged at 3, 6 and 12 months follow-up.
3.4. Safety
Safety data analysis was based on the 491 patients of the safety
population. Overall, LEV was well tolerated. At least one adverse
event (AE)was experienced by 53 (10.8%) of the patients during the
treatment period. Overall, 97 AEswere reported, of which 35 AEs in
19 patients (3.9% of the safety population) were classiﬁed as
serious. Table 3 lists the reported adverse events. A total of 18
(3.7%) patients discontinued the trial because of intolerable side
effects (irritability, dizziness, insomnia).
Most AEswere ofmild ormoderate intensity and known to occur
with LEV treatment.13 AEs regarding mood or affective symptoms
(restlessness, irritability or aggression, depression) were present in
15 of 491 patients (3.1%) often in combination. Other common AEs
were fatigue (1.2%) or gait instability (1%) or vertigo (1%). The AE
outcome was classiﬁed as ‘‘resolved’’ in 77.3%, ‘‘yet unresolved’’ in
7.6%, and ‘‘unknown’’ or ‘‘no information’’ in 15.2%. In two patients
irritability led to termination of the trial. There was no difference in
the starting dosage of LEV between patients with and without AEs.
Nine patients diedduring the course of the study.Noneof the deaths
reportedwere related to the intakeof Levetiracetamaccording to the
assessments of the investigator and the sponsor. Eight patients had
tobeadmitted to thehospital due to seizures (1.6%). In these, no case
of status epilepticus was reported and the outcome was resolved in
six and unknown in two. Themajority of serious adverse eventswas
classiﬁed as ‘‘unlikely’’ related to the studymedication (Table 3) and
consisted of medical events typically occurring in this age group.
At 12 months follow-up the self assessment of tolerability was
considered as ‘‘very good’’ by 70.1% of physicians and 62.9% of
patients in the PP population (Fig. 2).
3.5. Efﬁcacy
Efﬁcacy was analysed based on the PP population (n = 364),
which excluded patients with missing study visits. In the 12
months prior to entry to the study the mean monthly seizure
frequency was 7.0 (SD 8.7, range 1–85, median 4). Seizure
frequency was higher in younger elderly patients (65–74 years)
compared to older patients (75–84 years) (7.8  9.7 vs. 5.1  5.1,
t = 2.5, p < 0.05). Seizure frequency was lower in patients with a
duration of epilepsy of one year or less compared to those with 2–5
year duration of disease (5.8  7.2 vs. 8.6  8.6, t = 2.2, p < 0.05).
Mean total monthly seizure frequencywas 1.7 (SD 2.9, range 0–
29, median 1) at 3, 1.2 (SD 2.6, range 0–30, median 0) at 6, and 1.4(SD 6.6, range 0–99, median 0) at 12 months, a reduction of 75.7%,
82.9% and 80.0% relative to baseline. Using analysis of variancewith
‘‘time’’ as independent factor reduction of overall seizure frequency
compared to baseline was signiﬁcant (f(3) = 116.8, p< 0.0001)
(Fig. 3). Post hoc t-tests revealed that this was valid for all visits (3
month p< 0.0001, 6 month p < 0.0001, 12 months p< 0.0001).
There was no difference in seizure freedom rates at 12 months
between patients at 3000 mg/day and those on a daily dose of
2000 mg or less. A signiﬁcant reduction of seizures was seen in all
seizure types, in particular with secondary generalized tonic-clonic
seizures at 12 months follow-up (reduction of 88.2%, p< 0.0001).
Seizure frequency was slightly less reduced with simple partial
seizures (73.9%, 78.3% and 69.6% at 3, 6, and 12 months).
Seizure freedomover the preceding period of observation (i.e. 3,
6, or 12 months) was reported by 42% of patients at 3 in 57.7% at 6,
and 58% at 12 month follow-up visits. Overall, 28.6% of patients
became seizure free in the ﬁrst three months following introduc-
tion of Levetiracetam and had no further seizures over the 12
month study duration. Another 15.7% of patients reported seizure
[()TD$FIG]
Fig. 2. Self assessment of levetiracetam add-on therapy based on PP population (n = 364) in %.
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the study.
At the 12 month follow-up visit, efﬁcacy was rated as ‘‘good’’ or
‘‘very good’’ by 90.1% of physicians and 89.6% of patients (Fig. 2).
4. Discussion
This study had an open label, uncontrolled, observational
design and as such, conclusions of treatment effects of LEV in the
elderly can only be tentative. A randomized, double-blind
comparator controlled trial is ongoing to come to a more deﬁnite
conclusion.20 However, the data presented seems to justify such an
effort as adding LEV to a current AED regiment in elderly patients
with uncontrolled focal epilepsy was found to be associated with
only a small number of adverse effects, signiﬁcant reduction of
seizure frequency and was judged positively by the great majority
of patients and physicians.
Themain limitation of the study is the open-label, observational
design. Potential problems arise from various biases, the quality of
the data and the exploratory nature of the analysis. The lack of a
comparative patient group as a control, the open design possibly
causing treatment bias and the possible underreporting of adverse
[()TD$FIG]
Fig. 3. Efﬁcacy of levetiracetam add-on treatment in 364 elderly patients with focal
epilepsy. Mean monthly seizure frequency at baseline, 3, 6, and 12 months follow
up. Bars indicate SD.events only based on spontaneous reporting compared to
controlled trials might be additional problems affecting the
results. Another potential confounder of the present study was
that efﬁcacy analysis was based on the per protocol population,
which might exclude patients with a negative initial treatment
effect and bad tolerance. On the other hand, compared to
controlled clinical trials, observational studies offer greater access
to large, diverse populations giving a more naturalistic picture of
everyday practice. Patient selection in observational studies is less
inﬂuenced by the rigorous inclusion criteria of controlled trials and
they may be important to detect adverse reactions that are
uncommon. In addition, they may be valuable to obtain data upon
general acceptance of a drug. In fact, because of co-morbidities and
age-related issues patient recruitment in the elderly was a major
problem in previous controlled trials.21 Moreover, controlled trials
particularly in the ﬁeld of epilepsy often are too short to evaluate
long-term treatment responses.9
There are only four reports in small patient groups (n = 14–35)
using LEV in elderly patients with epilepsy and in all of these trials
LEV was used as ﬁrst AED in monotherapy.15–18 In these open,
observational or retrospective trials seizure freedom rates at 6–18
months follow-up ranged from61 to 82% and discontinuation rates
due to intolerability varied from 3 to 16%.15–18 In addition, the
safety and efﬁcacy data of the subsets of elderly (65 years)
patients receiving LEV as add-on therapy were reported from two
open-label, 16-week, phase IV trials.22,23 The 50%, 75% responder
rates and seizure freedom rates were 76.9, 56.9 and 40% in n = 7822
and 65.2, 46.4 and 31.9% in n = 6923 patients, respectively. In the
present study, seizure freedom at 12 months could be achieved in
58% of patients and drop-out rate due to adverse effects was 3.7%.
The relatively low seizure-freedom rate in our series is most likely
due to the difference in patient population. We only included
patients who failed at least one monotherapy. Therefore, our
population most certainly was more difﬁcult to treat given the
sharply declining probability that subsequent drugs succeed after
failure of monotherapy.24 In other hand, a 3-month seizure
freedom rate for all seizures of 75.7% in our trial was higher
compared to previous add-on LEV trials, again reﬂecting differ-
ences in patient population.22,23 The higher drop-out rate in most
previous monotherapy trials (i.e. 54% at 6 month in Brodie et al.13)
could be explained with differences in titration and by the fact that
K.J. Werhahn et al. / Seizure 20 (2011) 305–311310newly diagnosed patients might be more sensitive towards side
effects thanpatients that are alreadyused to anticonvulsive therapy.
In general, it should be noted that a large number of serious adverse
events can be explained by medical conditions, complications of
existing diseases, or death typically occurring in this age group.
Only 11% of all patients were treated with the highest
recommended daily dose of 3000 mg and two-thirds were
managed with doses between 1000 and 2000 mg per day. This
might reﬂect the good response to treatment of epilepsy occurring
in the elderly.2 Alternatively, old patients might require a lower
LEV dose as compared to young patients because of reduced
clearance. In support of the latter explanation, it has been shown
that equivalent LEV serum levels can be achieved in older adults
with a mean 40% lower dose than in young adults.25 Taken
together, the results of the present study seem to support the
notion that a low dose of LEV might be sufﬁcient in the elderly.
In adults, a number of double-blind, placebo-controlled clinical
trials have conﬁrmed that LEV is effective and well-tolerated as
add-on treatment in patients with focal epilepsy.12,26–28 However,
themean age of patients in these add-on trialswas around 36 years
making it difﬁcult to judge upon the efﬁcacy and tolerability of
levetiracetam in the elderly. In addition, differences in study
design and patient selection, with most patients having medically
refractory long-standing epilepsy and multiple AEDs, greatly
impede a comparison to the present study.
Comparison of individual observational studies is not viable
because each study includes different patient populations, adopts
different designs, and uses different analytical methods. With
these limitations in mind, how does efﬁcacy of add-on LEV
compare to observational trials using other AEDs? In this study,
complete seizure freedom was achieved in 58% and mean total
monthly seizure frequency dropped by 80.0% at 12months follow-
up. Cho et al.29 reported a mean reduction in mean seizure
frequency of 47% using topiramate at 12 months in young adults
with chronic epilepsy who failed 4.8 pervious AED treatments. In
the elderly (n = 222), lamotrigine in monotherapy at a mean daily
dose of 72 mg led to a mean reduction of 89% of seizure frequency
over a period of one year with only 15 adverse events in nine
patients.30 There may be biases towards a more favourable
outcome. For example, we do not know the reasons for drug
failure of the ﬁrst drug of those included. Some patients may have
been ‘‘pseudo-resistant’’ to the ﬁrst drug i.e. due to non-
compliance, insufﬁcient doses of the ﬁrst drug due to side-effects,
or wrong diagnosis with inappropriate treatment.31 Information
about other treatment changes, which may have occurred in
parallel with the change of medication under investigation, was
not collected during the trial and might have improved seizure
control. Nevertheless, taken together the results of this study
suggest that LEV add-on therapy is well tolerated and associated
with a signiﬁcant improvement of seizure control in elderly
patientswith partial epilepsies, which is in general agreementwith
previous long-term observational studies with this drug.32
Monotherapy remains the treatment of choice for newly
diagnosed epilepsy and polytherapy with more than one AED is
considered after at least one failure of a monotherapy regimen
only. This therapeutic strategy is driven by concerns of excessive
drug load and increased toxicitywhat is of particularly relevance in
elderly patients. Thus, combinations of AEDs should be carefully
selected based not only on efﬁcacy but also on a favourable
pharmacokinetic proﬁle and toxicity. From this perspective LEV
seems a favourable drug given its pharmacological proﬁle with
rapid and complete oral absorption, linear pharmacokinetics and a
low potential for clinically signiﬁcant pharmacokinetic drug
interactions.33 The results of our study support efforts to challenge
current treatment guidelines through randomized, controlled
trials in the elderly comparing LEV with other established AEDs.9Conﬂicts of interest
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